Moderna’s technology platform makes it possible to direct cells to express proteins without changing their genome or creating long term safety concerns.
|Primary Business Focus||Biotechnology - Pharmaceutical|
|Other Business Offering||In Vitro Diagnostics|
|Stephane Bancel||President/Founding CEO|
|Stephen Hoge||SVP Corp Dev't/New Drug Concepts|
|Louis O'Dea||Chief Medical Officer/Head RA|
|Divakar Ramakrishnan||SVP Process Dev't/Manufacturing/Quality|
* Downloads will not contain Personnel E-mail addresses
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of American City Business Journals.